Company news

BCAL Diagnostics Limited news in 2026

BCAL Diagnostics Limited's news releases, calls and decks from 2026, newest first.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

BCAL Welcomes Dr John Melki's Appointment to GSS Board

October 28, 2026

Results of Meeting

October 18, 2026

AGM 2026 Presentation

October 18, 2026

BREASTESTplus Research Presented at Lipidomic Conference

October 18, 2026

GSS: Response to Media Speculation & BCAL letter to GSS

October 16, 2026

Letter to Genetic Signatures Ltd Shareholders

October 14, 2026

Investor Presentation - Transforming Cancer Detection

October 5, 2026

Change in substantial holding

October 1, 2026

BREASTESTplus 2 clinically validated

September 29, 2026

BCAL Introduces Avantect Multi-Cancer Early Detection Test

September 22, 2026

Letter to Shareholders re Annual General Meeting

September 17, 2026

Notice of Annual General Meeting/Proxy Form

September 17, 2026

Clarification of BCAL's Position in Relation to GSS

September 9, 2026

BCAL Seeks Board Change at Genetic Signatures

September 2, 2026

Investor Presentation September 2026

September 2, 2026

Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM

August 31, 2026

Appendix 4E and Annual Report to shareholders

August 28, 2026

Appendix 4G and Corporate Governance Statement

August 28, 2026

BCAL Takes Interest in Genetic Signatures to 18.46%

August 25, 2026

Change in Substantial Shareholder Notice for GSS

August 25, 2026

Notification regarding unquoted securities - BDX

August 25, 2026

BCAL Secures Funding for FY2027 Update

August 21, 2026

Notification regarding unquoted securities - BDX

August 21, 2026

Proposed issue of securities - BDX

August 21, 2026

Bioshares Conference Investor Presentation

August 5, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 29, 2026

BCAL to Acquire Shares in Genetic Signatures

July 1, 2026

BCAL Secures Funding for FY2027

June 28, 2026

BCAL Develops New Blood Test for Breast Cancer Recurrence

June 17, 2026

BCAL Launches Early Detection Cancer Platform

May 19, 2026

BCAL Appoints Anne-Louise Arnett as Chief Executive Officer

May 10, 2026

BCAL Accelerates Rollout of Avantect Early Detection Tests

March 25, 2026

Half Yearly Report and Accounts

February 17, 2026

Shareholder Update

February 4, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 20, 2026

Decks in 2026